Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,
Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,
Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Dasari A
Authors: Dasari A, Halperin D, Coya T, Mahvash A, Zorrilla I,
Keywords: Foregut NETs, ribociclib, cdk 4/6,
Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Dasari A, Mehta K, Sorbye H, Yao J,
Keywords: Grade 3, NE carcinoma,